Abstract
During the post-thalidomide era of medicines development there has emerged a general consensus that the pharmaceutical market place demands careful regulation. Few commentators would today seriously question the view that, world-wide, the interests of the medicine consuming public are best safeguarded by professionally administered control over the processes by which new medicines enter or are withdrawn from, the therapeutic armamentarium. Table 6.1 lists the central activities of regulatory authorities concerned with this area.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Grahame-Smith D G. Report of the Working Party on Adverse Drug Reactions to the Committee on Safety of Medicines 1983; London, DHSS.
Grahame-Smith D G. Report on the Working Party on Adverse Drug Reactions to the Committee on Safety of Medicines II 1986; London, DHSS.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Griffin, J.P. (1988). The Impact of Regulations on Drug Development. In: Walker, B.C., Walker, S.R. (eds) Trends and Changes in Drug Research and Development. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-2659-2_6
Download citation
DOI: https://doi.org/10.1007/978-94-009-2659-2_6
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-85200-839-3
Online ISBN: 978-94-009-2659-2
eBook Packages: Springer Book Archive